Evaluation of berberine pellet effect on clinical recovery time in COVID-19 outpatients: A pilot clinical trial | ||
| Avicenna Journal of Phytomedicine | ||
| دوره 13، شماره 3، مرداد و شهریور 2023، صفحه 265-279 اصل مقاله (1.01 M) | ||
| نوع مقاله: Original Research Article | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2022.21539 | ||
| نویسندگان | ||
| Soodabeh Omidvar Tehrani1؛ Mahboobeh Ghasemzadeh Rahbardar2؛ Kamran Shoorgashti1؛ Mohammad Javad Dehghan Nayeri3؛ Amir Hooshang Mohammadpour* 4؛ Hossein Hosseinzadeh* 5 | ||
| 1School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 2Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 3Infection Control & Hand Hygiene Research Center, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 4Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 5Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| چکیده | ||
| Objective: Severe disease onset of COVID-19 may result in alveolar injury and respiratory failure. Apoptosis and inflammation are the main causes of respiratory distress syndrome. Berberine is used in medicine as an analgesic, anti-asthmatic, anti-inflammatory, and antiviral. In the current investigation, the effect of berberine on COVID-19 outpatients was studied. Materials and Methods: The present clinical trial was performed on 40 outpatients who were randomly assigned to berberine (300 mg, TID, 2 weeks) (n=19) or placebo groups (n=21). Both groups received standard therapy and they were monitored on days 3, 7, and 14 after the beginning of the therapy for clinical symptoms’ improvement, quantitative CRP, lymphopenia, CBC, and SpO2. The severity and frequency of these symptoms and the level of the parameters were statistically compared between the two groups. Results: On days (0, 3, 7, and 14, there was no significant difference between the berberine and placebo groups in the improvement of clinical symptoms (cough, shortness of breath, nausea, loss of smell and taste, diarrhea, dizziness, sore throat, stomachache, body aches, and body temperature), quantitative CRP, lymphopenia, WBC, neutrophils, platelets, or SpO2. Conclusion: Berberine (300 mg, TID, two weeks) is ineffective in treating COVID-19. More research with a larger sample size is needed to investigate different berberine dosages in other pharmaceutical formulations. | ||
| کلیدواژهها | ||
| Clinical trial؛ Berberis vulgaris؛ Barberry؛ Coronavirus disease؛ Lymphopenia؛ Antiviral | ||
| مراجع | ||
|
Asbaghi O, Ghanbari N, Reiner Ž, Amirani E, Hallajzadeh J, Mirsafaei L, Asemi Z. 2020. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN, 38: 43-49. Babaei F, Mirzababaei M, Nassiri‐Asl M, Hosseinzadeh H. 2021. Review of registered clinical trials for the treatment of COVID‐19. Drug Dev Res, 82: 474- 493. Babaei F, Nassiri‐Asl M, Hosseinzadeh H. 2020. Curcumin (a constituent of turmeric): New treatment option against COVID‐19. Food Sci Nutr, 8: 5215-5227. Boozari M, Hosseinzadeh H. 2021. Natural products for COVID‐19 prevention and treatment regarding to previous coronavirus infections and novel studies. Phytother Res, 35: 864-876. Omidvar Tehrani et al. AJP, Vol. 13, No. 3, May-Jun 2023 278 Brendler T, Al‐Harrasi A, Bauer R, Gafner S, Hardy ML, Heinrich M, Hosseinzadeh H, Izzo AA, Michaelis M, Nassiri‐Asl M. 2021. Botanical drugs and supplements affecting the immune response in the time of COVID‐19: Implications for research and clinical practice. Phytother Res, 35: 3013-3031. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, Xing F, Liu J, Yip CCY, Poon RWS. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. The Lancet, 395: 514-523. Dkhil M, Al-Quraishy S. 2014. Evaluation of antiviral activity of berberine against herpes simplex viruses. J Pure Appl Microbiol, 8: 155-159. Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. 2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect, 9: 558-570. García LF. 2020. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol, 11: 1441. Ghareeb DA, Saleh SR, Seadawy MG, Nofal MS, Abdulmalek SA, Hassan SF, Khedr SM, AbdElwahab MG, Sobhy AA, Yassin AM. 2021. Nanoparticles of ZnO/Berberine complex contract COVID19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity. J Pharm Investig, 51: 735-757. Gorbalenya AE, Baker SC, Baric R, Groot RJd, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW. 2020. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. Nat Microbiol, Epub ahead of print. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395: 497-506. Huang L, Zhang X, Ma X, Zhang D, Li D, Feng, J, Pan X, Lü J, Wang X, Liu X. 2018. Berberine alleviates endothelial glycocalyx degradation and promotes glycocalyx restoration in LPS-induced ARDS. Int Immunopharmacol, 65: 96- 107. Imanshahidi M, Hosseinzadeh H. 2008. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res, 22: 999-1012. Imenshahidi M, Hosseinzadeh H. 2016. Berberis vulgaris and berberine: an update review. Phytother Res, 30: 1745-1764. Imenshahidi M, Hosseinzadeh H. 2019. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res, 33: 504-523. Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, Ostro R, Banovcin P. 2020. Immune parameters and COVID-19 infection– associations with clinical severity and disease prognosis. Front Cell Infect Microbiol, 10: 364. Kikkert M. 2020. Innate immune evasion by human respiratory RNA viruses. J Innate Immun, 12: 4-20. Li Z, Zheng J, Zhang N, Li C. 2016. Berberine improves airway inflammation and inhibits NF-κB signaling pathway in an ovalbumin-induced rat model of asthma. J Asthma, 53: 999-1005. Liu H, You L, Wu J, Zhao M, Guo R, Zhang H, Su R, Mao Q, Deng D, Hao Y. 2020. Berberine suppresses influenza virus‐ triggered NLRP3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS. J Leukoc Biol, 108: 253-266. Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. 2020. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. Am J Trop Med Hyg, 103: 561-563. Rameshrad M, Ghafoori M, Mohammadpour AH, Nayeri MJD, Hosseinzadeh H. 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Naunyn-Schmiedeb Arch Pharmacol, 393: 1137-1152. Sánchez‐Mendoza ME, Castillo‐Henkel C, Navarrete A. 2008. Relaxant action mechanism of berberine identified as the active principle of Argemone ochroleuca Sweet in guinea‐pig tracheal smooth muscle. J Pharm Pharmacol, 60: 229-236. Shah VK, Firmal P, Alam A, Ganguly D, Effect of berberine on COVID-19 outpatients AJP, Vol. 13, No. 3, May-Jun 2023 279 Chattopadhyay S. 2020. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol: 11, 1949. Singhal T. 2020. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr, 87: 281-286. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. 2021. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J, 42: 2270-2279. Varghese FS, Thaa B, Amrun SN, Simarmata D, Rausalu K, Nyman TA, Merits A, McInerney GM, Ng LF, Ahola T. 2016. The antiviral alkaloid berberine reduces chikungunya virus-induced mitogenactivated protein kinase signaling. J Virol, 90: 9743-9757. Wang H, Li K, Ma L, Wu S, Hu J, Yan H, Jiang J, Li Y. 2017. Berberine inhibits enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy. Virol J, 14: 2. Wang L. 2020. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect, 50: 332-334. Wu Y, Li Jq, Kim Yj, Wu J, Wang Q, Hao Y. 2011. In vivo and in vitro antiviral effects of berberine on influenza virus. Chin J Integr Med, 17: 444-452. Yan YQ, Fu YJ, Wu S, Qin HQ, Zhen X, Song BM, Weng YS, Wang PC, Chen XY, Jiang ZY. 2018. Anti‐influenza activity of berberine improves prognosis by reducing viral replication in mice. Phytother Res, 32: 2560-2567. Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. 2021. The proinflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog, 153: 104799. Yoo JH. 2020. The fight against the 2019- nCoV outbreak: an arduous march has just begun. J Korean Med Sci, 35: e56. Zhang B, Chen M, Chen X, Cao K, You Y, Qian Y, Yu W. 2021. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19. Br J Surg, 108: e9-e11. Zou K, Li Z, Zhang Y, Zhang Hy, Li B, Zhu Wl, Shi Jy, Jia Q, Li Ym. 2017. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin, 38: 157-167. | ||
|
آمار تعداد مشاهده مقاله: 12,404 تعداد دریافت فایل اصل مقاله: 2,314 |
||